Philipp Spycher

Company: Araris Biotech AG

Job title: Chief Scientific Officer and Co-Founder

Seminars:

Linker Matters: Highly Stable & Efficient ADCs Utilizing Novel Native Antibodies & Peptide Linker Technology to Improve PK Exposure, Therapeutic Efficacy & Tolerability 2:00 pm

A novel peptide linker technology for site-specific payload conjugation will be introduced that enables the generation of antibody-drug conjugates (ADCs) from native antibodies in one step Resulting ADCs show antibody-like PK exposure with excellent activity and tolerability Topoisomerase-1 inhibitor ADCs were generated showing superior efficacy vs. trastuzumab deruxtecan in several animal models, highlighting the potential…Read more

day: Conference Day One - Track 1 - PM